Evaluation of CD69 expression as a prognosticator in chronic lymphocytic leukemia

El-Hadi, Emad A Abd; El-Sakhawy, Yasmin N; Osman, Ashraf

doi:10.4103/1110-1067.164725

Cited by 3 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD69 positive CLL patients got chemotherapy was the predominant category, and low CD69 expression was necessary to predict the longer progression free survival. In research done at Egypt on 153 (B-CLL) patients enrolled in Mansoura Oncology Center, Aref et al (23) stated in accordance with these results that advanced Ria stage and greater B2M level were related to higher CD69% (2). Additionally, another study conducted on 40 B-CLL patients from Ain Shams University Hospitals, demonstrated highly significant elevation of CD69% expression between their studied groups with highly significant positive correlation between CD69% and hepatomegaly, Rai stage and CD38% expression.…”

Section: Discussionmentioning

confidence: 70%

Prognostic Relevance of CD69, Vascular Endothelial Growth Factor and Thymidine Kinase in B-Chronic Lymphocytic Leukemia

Noreldin¹,

Zaiat²,

Ahmedy³

2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: B-chronic-lymphocytic-leukemia (B-CLL) is a heterogeneous illness with a varied clinical history. Some individuals don't require therapy while others have an aggressive disease. Researchers discovered several prognostic biomarkers to help clinicians make decisions about whose patients will be in need to start treatment. Developing immunophenotyping markers such as CD69 and other serum markers such as TK and VEGF are evolving over time.Objective: This study aimed to assess relevance of CD69 as prognostic indicator in CLL cases and its association with Vascular-endothelial-growth factor (VEGF) and Thymidine-kinase (TK) activity. Methods: The research had 80 patients with B-CLL and 17 healthy controls. All subjects underwent routine laboratory investigations, flowcytometric analysis of CLL panel, CD38 and CD69 and TK activity and VEGF level by ELISA. Results: CD69 %, VEGF and TK were significantly higher in patients than in controls. Patients who required treatment had significantly higher CD69% and elevated levels of VEGF and TK than patients who were untreated. Correlation between CD69% with different parameters revealed significant positive correlation between CD69% and age, modified Rai staging, TLC, lymphocyte, B2 microglobulin, LDH, Coombs`test, receiving chemotherapy, CD 38/19%, VEGF and TK. CD69% at cut off levels of > 45% can significantly detect time to start chemotherapy with sensitivity and specificity of 88.89% and 77.27%. Regression analysis showed that age, modified Rai staging, lymphocyte count and HB level were independent variables that can predict CD69 expression. Conclusions: CD69, TK and VEGF could be considered as poor prognostic markers adding a new option for development of new prognosis score system.

show abstract

Section: Discussionmentioning

confidence: 70%

Prognostic Relevance of CD69, Vascular Endothelial Growth Factor and Thymidine Kinase in B-Chronic Lymphocytic Leukemia

Noreldin¹,

Zaiat²,

Ahmedy³

2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

CD markers variations in chronic lymphocytic leukemia: New insights into prognosis

Vosoughi

Bagheri

Hosseinzadeh

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is one of the most commonly occurring adult leukemias that is associated with clonal accumulation of mature apoptosis-resistant B-cells in bone marrow, peripheral blood, and specific tissues. Different pathogenesis factors can contribute to the aggression of the clinical course in this disease.Cytogenetic abnormalities and surface biomarkers of neoplastic CLL cells can be effective in the outcome of CLL, and the examination of changing CD markers expressions in the progression of CLL can be related to the prognosis of this disease. Changing expression levels of CD markers on lymphocytes and other cells in CLLpatients can play a role in the aggressive clinical outcomes such as organomegaly, immunodeficiency, and advanced disease stages through their interaction with CLL microenvironment. Given the involvement of CD markers in the pathogenesis of CLL, it can be stated that recognizing the expression changes of CD markers in the cells involved in CLL can be a proper approach to evaluate prognosis among these patients.

show abstract

Prognostic relevance of CD69 expression in B cell chronic lymphocytic leukemia

et al. 2018

View full text Add to dashboard Cite

Evaluation of CD69 expression as a prognosticator in chronic lymphocytic leukemia

Cited by 3 publications

References 3 publications

Prognostic Relevance of CD69, Vascular Endothelial Growth Factor and Thymidine Kinase in B-Chronic Lymphocytic Leukemia

Prognostic Relevance of CD69, Vascular Endothelial Growth Factor and Thymidine Kinase in B-Chronic Lymphocytic Leukemia

CD markers variations in chronic lymphocytic leukemia: New insights into prognosis

Prognostic relevance of CD69 expression in B cell chronic lymphocytic leukemia

Contact Info

Product

Resources

About